KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.1157
+0.0036 (3.21%)
May 6, 2026, 2:25 PM EDT - Market open
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
107.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Cue Biopharma | 27.47M |
| Pyxis Oncology | 13.86M |
| Coya Therapeutics | 7.95M |
| NRx Pharmaceuticals | 1.23M |
| NeOnc Technologies Holdings | 39.99K |
KALA News
- 15 days ago - Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine - GlobeNewsWire
- 5 weeks ago - Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - GlobeNewsWire
- 5 weeks ago - KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - GlobeNewsWire
- 5 weeks ago - EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch - Benzinga
- 7 weeks ago - Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - GlobeNewsWire
- 7 weeks ago - Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - Newsfile Corp
- 2 months ago - Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents - Newsfile Corp
- 2 months ago - Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates - GlobeNewsWire